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Abstract 
Objective: Parkinson’s disease is a common, age‑related, neurodegenerative disease, affecting gait and other motor 
functions. Technological developments in consumer imaging are starting to provide high‑quality, affordable tools for 
home‑based diagnosis and monitoring. This pilot study aims to investigate whether a consumer depth camera can 
capture changes in gait features of Parkinson’s patients. The dataset consisted of 19 patients (tested in both a practi‑
cally defined OFF phase and ON phase) and 8 controls, who performed the “Timed‑Up‑and‑Go” test multiple times 
while being recorded with the Microsoft Kinect V2 sensor. Camera‑derived features were step length, average walking 
speed and mediolateral sway. Motor signs were assessed clinically using the Movement Disorder Society Unified 
Parkinson’s Disease Rating Scale.
Results: We found significant group differences between patients and controls for step length and average walking 
speed, showing the ability to detect Parkinson’s features. However, there were no differences between the ON and 
OFF medication state, so further developments are needed to allow for detection of small intra‑individual changes in 
symptom severity.
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Introduction
Parkinson’s disease (PD) is the second most common 
age-related neurodegenerative disease, which markedly 
affects patients’ motor as well as a variety of non-motor 
functions. Various gait features are indicators of PD 
severity, such as a reduced step length, walking speed [1–
4] and movement in the transverse plane [5, 6]. The dis-
ease severity can be scored clinically using standardized 
assessments, such as the Movement Disorder Society 
Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) 
[7]. Administering this scale is time consuming and 
resource intensive for both patients and clinicians and is 
also susceptible to intra- and inter-rater variability due to 
the subjective nature of clinical scoring [8].
Gait features can be measured objectively with 3D cam-
era recordings. One promising low-cost consumer device 
is the Microsoft Kinect for Xbox One sensor (V2), which 
records RGB-depth data and tracks 25 anatomical land-
marks in 3D space without the need for body-attached 
sensors. For an example, see Fig.  1A. Its accuracy and 
consistency have been validated with a gold standard sys-
tem of optical motion capture (Vicon) [9, 10]. In recent 
studies, Kinect derived kinematic features were used to 
detect group-level differences of motor patterns between 
healthy controls and persons with PD for fine motor tasks 
such as finger tapping [11] and gait tasks [12, 13], includ-
ing the “Timed Up-and-Go” (TUG) test [14]. However, 
these studies did not look at symptom severity changes 
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Detection of variation in individual symptom sever-
ity at home, could be a useful aid in monitoring dis-
ease progression and treatment effectiveness, giving 
clinicians time to focus on other aspects of patient 
care. Especially in times of a pandemic, benefits of 
home-based assessments become increasingly evident 
[15]. This would be especially valuable for persons 
with PD since considerable symptom fluctuations can 
be present, depending on factors such as the efficacy 
of medication, stress, fatigue or anxiety [16]. This 
study aims to investigate to what extent kinematic gait 
parameters, as derived with the Kinect, reflect intra-
individual motor function differences ON and OFF 





Data was collected in participants of the Park in Shape 
study [17], a randomized controlled trial evaluating the 
effectiveness of aerobic exercise on PD symptoms. The 
subjects mean age was 59.17 ± 8.22 years (SD) ranging 
30 to 75 years. Subjects had idiopathic PD diagnosed by 
a neurologist, with Hoehn and Yahr (H&Y) stages I–II 
(tested off medication), no cognitive impairment (Mini-
Mental State Examination > 24) and were stable on dopa-
minergic medication dose for at least 1 month. Exclusion 
criteria and a detailed design of the Park in Shape study 
can be found in the published protocol [17].
Healthy controls were recruited at the Radboud Uni-
versity Medical Center. The mean age was 34.57 ± 12.18 
years (SD) with a range of 21 to 57 years. Exclusion crite-
ria were neurodegenerative diseases or any other disease 
affecting motor function.
Data collection
Study procedure Participants abstained from taking their 
regular PD medication for 12  h before the first assess-
ment (i.e. a practically defined OFF medication state). 
The motor symptoms were assessed using the MDS-
UPDRS-III and participants performed the TUG-test 
three times. Then, participants took their regular medi-
cation and repeated both the MDS-UPDRS-III and the 
TUG-test after 90 min (ON medication state).
Timed up-and-go test The TUG-test is a standard 
movement task to assess balance and mobility [18]. The 
task consists of five sequential motor sub-tasks: stand-
ing up from a seated position, standing up, walking three 
meters forward as fast as possible, turning around and 
walking back to sit down again.
Data acquisition Test performance was recorded with 
the Kinect V2 sensor (Microsoft, Redmond WA, USA), 
which is able to record RGB-depth data and track 25 joint 
positions of persons in frame with a framerate of 30 Hz 
within a range of 0.5m up to 4.5m with a depth resolution 
of 512 × 424 pixels and a field of view of 70.6◦ × 60◦ . The 
Kinect Sensor was placed shortly after the turning point 
of the TUG-test at roughly the participant’s eye-level.
Data analysis
A flowchart of the data analysis pipeline is displayed in 
Fig. 1B. For this pilot study only the first walking phase 
of the TUG-test was used, since its signal to noise 
ratio was the highest. Both the stand-up and sit-down 
phase were at the edge of the Kinect sensor range and 
therefore more noise corrupted. The turning phase 
occurred at the other edge of the sensor range, where 
Fig. 1 Landmark data & data analysis pipeline. A Example of a 
landmark data frame of a walking participant. Landmarks are 
represented in white. B Complete data analysis pipeline from 
data acquisition until correlation analysis of gait features and 
MDS‑UPDRS‑III score
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the landmark tracking especially for the legs appeared 
to be unreliable. The second walking phase was also 
excluded, since the Kinect landmark tracking assumes 
that a person faces the camera, leading to less precise 
estimations.
Data processing From each recording, we extracted 
the 3D landmark time-series using a software tool 
built and provided by Motognosis based on the Kinect 
software development kit [19].
To avoid confounding from differing camera posi-
tions, we normalized landmark data with respect to 
camera roll and pitch.
Landmark signals from missing frames were interpo-
lated linearly.
In order to cleanly extract the first walking phase, 
we segmented recordings according to the following 
procedure. The walking phase is characterized by peri-
odic increase and decrease of the anterior-posterior 
distance between the feet. Therefore, we defined the 
start of the walking phase as the frame, in which the 
distance between the ankles exceeded a threshold of 
0.1 meters for the first time.
The walking phase ends, as the participants starts to 
turn around. Therefore we defined it as the frame in 
which the horizontal projection of the shoulder dis-
tance starts to decline strongly. This decline is best 
seen as a negative peak in the second derivative (accel-
eration) of the shoulder distance.
Features
We used three gait features: walking speed, step length 
and mediolateral sway. Features were extracted using 
the Motognosis Labs software (Motognosis GmbH, 
Berlin), which was validated previously [9, 19] and 
averaged over all recordings of an individual per medi-
cation state. Additionally feature validation was done 
by visual inspection and outlier detection.
Walking speed The average walking speed was cal-
culated by computing the time of participants walk-
ing phase and computing the Euclidean distance of the 
base of the spine from the first to the last frame.
Step length The step length is defined as the distance 
between the ankle landmarks, while both feet are on 
the ground. It was extracted with the Motognosis Labs 
software by finding the stance phases for both feet. To 
increase stance phase accuracy a velocity threshold 
was introduced and additional step length thresholds 
were implemented to filter out outliers.
Mediolateral sway We extracted the mediolateral 
sway by calculating the standard deviation of the 
mediolateral movement of the base of the spine.
Statistical analysis
To investigate the correlation between the MDS-UPDRS-
III score and the gait features, we calculated Spearman’s 
rank correlation coefficient for both the ON and OFF 
condition. Furthermore, we used t-tests (paired tests in 
case of patients in ON and OFF condition) to investigate 
the group differences per extracted feature. We calculated 
the effect size of group differences as Cohen’s d. The sta-
tistical tests were not corrected for multiple comparisons 
as the study was explorative and descriptive in nature. 
Additionally the group difference in MDS-UPDRS-III 
score was calculated to ensure that disease severity dif-
fered significantly between the ON and OFF state.
Results
Data
We included 19 persons with PD and 8 healthy controls.
Of the 145 total recordings, 128 recordings were used 
for analysis. We excluded recordings if the landmark 
data could not be extracted, the participant ran during 
the walking phase or if the participant had an atypical 
response to the medication, where the MDS-UPDRS-III 
score increased after taking medication. More record-
ings from TUG tests performed in ON state than in OFF 
state had to be excluded leading to the following data 
distribution:
• PD OFF: 60 recordings from 18 persons
• PD ON: 44 recordings from 12 persons
• control 24 recordings from 8 persons
Main results
The main findings are displayed in Table  1. The MDS-
UPDRS-III group difference between ON and OFF group 
was significant (ON: 24.5 ± 14.4 vs. OFF: 34.9 ± 15.5, 
p < 0.0001), indicating a clinical discernible medication 
effect. There were significant group differences between 
PD patients (both ON and OFF) and controls, for the 
features step length and walking speed with effect sizes 
larger than 1 for all comparisons. Within the PD group, 
intra-individual differences and gait parameters between 
the ON and OFF state were not statistically significant.
For associations between extracted features and disease 
severity, only the correlation of the mediolateral sway 
with the MDS-UPDRS-III score in the OFF group was 
significant (r = 0.599, p = 0.01).
Fig. 2 shows the MDS-UPDRS-III score plotted against 
the step length for participants in ON and OFF state. 
For six of the twelve participants (with available ON 
and OFF recordings), step length increased after taking 
medication.
Page 4 of 6van Kersbergen et al. BMC Res Notes          (2021) 14:329 
Discussion
In our sample, the Kinect Sensor in combination with 
Motognosis Labs software was capable of extracting 
several gait features in PD patients during a functional 
mobility test. There were significant differences in step 
length and average speed between patients with PD and 
controls, with a large effect size (Cohen’s d > 1 ). This 
confirms that the Kinect sensor is a promising tool to 
quantify PD-specific gait behaviour [2, 4, 6]. However, 
although a medication effect could be detected clini-
cally, there were no significant differences in task fea-
tures between the OFF and ON conditions.
This suggests that the current setup is not suffi-
ciently sensitive to relatively small differences in motor 
functioning between the ON and OFF condition in 
persons with mild symptoms (only H&Y stages I and 
II included). However, in almost all participants the 
step length either increased or did not change strongly 
in the ON condition, indicating a trend towards an 
increased step length for reduced MDS-UPDRS-III 
scores, which is in line with previous research [1, 2, 
14]. Interestingly, the strongest correlation with MDS-
UPDRS-III was found for mediolateral sway. This was 
not expected, since Parkinsonian gait is characterized 
by stiffness and decreased transversal motion. A possi-
ble explanation might be the compromised balance of 
people with PD [20, 21] resulting in more compensa-
tory movements.
The current study may well have been underpowered to 
detect differences intraindividual gait differences in ON 
versus OFF. We should also point out that we included 
patients with relatively mild disease, where the differ-
ences between the ON and the OFF state, although clini-
cally evident, were not very large. Possibly some of these 
differences were caused by symptoms that are not directly 
reflected in gait. Much larger differences are typically 
seen in more advanced patients who experience response 
fluctuations, and it is possible that quantitative gait 
analysis using the remote kinematic analysis can detect 
relevant differences in such a more severely affected pop-
ulation. However, the practical use of these camera sys-
tems would mainly lie in ambulatory follow-up of disease 
progression or medication effect, necessitating sufficient 
sensitivity on an individual level. Since PD is a complex 
disease with a very heterogeneous presentation, increas-
ing the number of outcome parameters and combining 
them in a single model may enable better detection of 
intra-individual differences. Using an adapted version of 
the TUG, such that the whole sequence can be success-
fully parametrized, or additional instrumentally assessed, 
standardized motor tasks such as the Short Physical 
Table 1 Results
Metric Step length (m) Avg. speed (m/s) Mediolateral sway (cm)
Mean HC (SD) 0.776 (0.091) 1.357 (0.218) 1.544 (0.690)
Mean OFF (SD) 0.613 (0.102) 1.024 (0.192) 1.692 (0.526)
Mean ON (SD) 0.664 (0.118) 1.005 (0.186) 1.787 (0.610)
Difference OFF‑HC (rel. diff.) ‑0.16 (5.84%) − 0.333 (6.98%) 0.148 (2.29%)
Difference ON‑HC (rel. diff.) − 0.111 (3.87%) − 0.351 (7.44%) 0.243 (3.65%)
Difference OFF‑ON (rel. diff.) − 0.051 (2.00%) 0.019 (0.46%) − 0.095 (1.36%)
p‑value of t‑test OFF‑HC (Cohen’s d) 0.001 (− 1.643) < 0.001(− 1.665) 0.552 (0.256)
p‑value of t‑test ON‑HC (Cohen’s d) 0.047 (− 1.004) 0.001 (‑1.797) 0.418 (0.383)
p‑value of t‑test OFF‑ON (Cohen’s d) 0.218 (− 0.461) 0.792 (0.010) 0.654 (− 0.166)
Corr. coef. OFF with UPDRS (p‑value) 0.08 (0.77) 0.01 (0.97) 0.599 (0.01)
Corr. coef. ON with UPDRS (p‑value) − 0.530 (0.09) − 0.260 (0.44) 0.361 (0.28)
























Fig. 2 Comparison of step length parameter in ON and OFF state, 
lines connect measurements in ON and OFF state. Red lines represent 
a decreased step length after taking medication, green lines 
represent an increased step length
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Performance Battery [22] could expand on the kinematic 
features. Because the hypothesized intra-individual dif-
ferences are likely small, standardized movement tests 
have an advantage over free movement by producing 
comparable, clean data and forcing a range of different 
movement patterns.
Conclusion
We were able to detect group differences in gait features 
between people with PD and healthy controls using the 
Kinect depth camera. However, the current task setup 
and analysis approach lacks sensitivity to detect small 
intra-individual changes in symptom severity.
Limitations
Limitations of this study include the small sample size, 
subjects with relatively mild symptoms and a not com-
plete age match with the control population. The stand-
ard outcome for the TUG (task duration) could not be 
analysed because of missing frames at the beginning of 
the recording.
Abbreviations
PD: Parkinson’s disease; TUG : Timed Up‑and‑Go; MDS‑UPDRS: Movement 




JVK performed the analysis, was a major contributor in interpreting the results 
and was the main contributor in writing the manuscript. KO, HMR and SMM 
wrote and made available the Motognosis Labs algorithm and aided in the 
interpretation of the results. NMV, BRB, MMG and SO designed the study. 
NMV and NK collected the data. SZ, SO and MMG were major contributors in 
interpreting the results and writing the manuscript. All authors reviewed the 
manuscript. All authors read and approved the final manuscript.
Funding
This study was supported by a VIDI research grant from the Netherlands 
Organization for Scientific Research (Grant No. 016.116.371) to SO.
Availability of data and materials
The datasets generated and analysed during the current study are available 
from the authors upon reasonable request. There are limitations with regard to 
raw RGB and depth data because of identifiability of patients.
Declarations
Ethics approval and consent to participate
The study protocol was approved by the medical ethics committee of 
Radboud University Medical Center, Nijmegen, the Netherlands. All subjects 




KO, HMR and SMM work at Motognosis GmbH. The company was not involved 
in the study design and did not have influence on the decision to publish. All 
other authors declare that they have no competing interests.
Author details
1 Eindhoven University of Technology, 5612 AJ Eindhoven, The Netherlands. 
2 Department of Neurology, Radboud University Medical Center, Geert 
Grooteplein Zuid 10, 6525 GA Nijmegen, The Netherlands. 3 Motognosis 
GmbH, Schönhauser Allee 177, 10119 Berlin, Germany. 4 Sleep Medicine Center 
Kempenhaeghe, Sterkselseweg 65, 5591 VE Heeze, The Netherlands. 5 Neuro‑
Cure Clinical Research Center, Charité – Universitätsmedizin Berlin, Corporate 
Member of Freie Universität Berlin, Humboldt‑Universität zu Berlin, and Berlin 
Institute of Health, Berlin, Germany. 6 Experimental and Clinical Research 
Center, Charité ‑ Universitätsmedizin Berlin Corporate Member of Freie 
Universität Berlin, Humboldt‑Universität zu Berlin, and Berlin Institute of Health 
and Max Delbrück Center for Molecular Medicine, Berlin, Germany. 
Received: 29 March 2021   Accepted: 16 August 2021
References
 1. Nelson A, Zwick D, Brody S, Doran C, Pulver L, Rooz G, Sadownick M, 
Nelson R, Rothman J. The validity of the GaitRite and the functional 
ambulation performance scoring system in the analysis of Parkinson gait. 
NeuroRehabilitation. 2002;17:255–62.
 2. Williams A, Peterson D, Earhart G. Gait coordination in Parkinson 
disease: effects of step length and cadence manipulations. Gait Posture. 
2013;38:340–4.
 3. Kimmeskamp S, Hennig E. Heel to toe motion characteristics in Parkinson 
patients during free walking. Clin Biomech. 2001;16:806–12.
 4. Bohnen N, Frey K, Studenski S, Kotagal V, Koeppe R, Scott P, Albin R, Müller 
M. Gait speed in Parkinson disease correlates with cholinergic degenera‑
tion. Neurology. 2013;81:1611–6.
 5. Murray M, Sepic S, Gardner G, Downs W. Walking patterns of men with 
parkinsonism. Am J Phys Med. 1987;57:278–94.
 6. Morrs M, Huxham F, McGinley J, Dodd K, Iansek R. The biomechanics and 
motor control of gait in Parkinson disease. Clin Biomech. 2001;16:459–70.
 7. Movement Disorder Society Task Force on Rating Scales for Parkinson’s 
Disease. The unified Parkinson’s disease rating scale (UPDRS): status and 
recommendations. Mov Disord. 2003;81:738–50.
 8. Post B, Merkus MP, de Bie RM, de Haan RJ, Speelman JD. Unified Par‑
kinson’s disease rating scale motor examination: are ratings of nurses, 
residents in neurology, and movement disorders specialists interchange‑
able? Mov Disord. 2005;20:1577–84.
 9. Otte K, Kayser B, Mansow‑Model S, Verrel J, Paul F, Brandt A, Schmitz‑
Hübsch T. Accuracy and reliability of the kinect version 2 for clinical 
measurement of motor function. PLoS ONE. 2016;11:e0166532.
 10. Clark RA, Pua YH, Oliveira CC, Bower KJ, Thilarajah S, McGaw R, Hasanki 
K, Mentiplay BF. Reliability and concurrent validity of the Microsoft Xbox 
One Kinect for assessment of standing balance and postural control. Gait 
Posture. 2015;42:210–3.
 11. Buongiorno D, Bortone I, Cascarano GD, Trotta GF, Brunetti A, Bevilacqua 
V. A low‑cost vision system based on the analysis of motor features for 
recognition and severity rating of Parkinson’s disease. BMC Med Inform 
Decis Making. 2019;19:243.
 12. Eltoukhy M, Kuenze C, Oh J, Jacopetti M, Wooten S, Signorile J. Microsoft 
kinect can distinguish differences in over‑ground gait between older per‑
sons with and without Parkinson’s disease. Med Eng Phys. 2017;44:1–7.
 13. Dranca L, de Mendarozketa LDAR, Goni A, Illarramendi A, Gomez IN, Alva‑
rado MD, Rodiguez‑Oroz MC. Using kinect to classify Parkinson’s disease 
stages related to severity of gait impairment. BMC Bioinform. 2018;19:471.
 14. Tan D, Pua Y‑H, Balakrishnan S, Scully A, Bower KJ, Prakash KM, Tan 
E‑K, Chew J‑S, Poh E, Tan S‑B, Clark RA. Automated analysis of gait and 
modified timed up and go using the Microsoft Kinect in people with 
Parkinson’s disease: associations with physical outcome measures. Med 
Biol Eng Comput. 2019;57:369–77.
 15. Bloem BR, Dorsey ER, Okun MS. The coronavirus disease 2019 crisis as 
catalyst for telemedicine for chronic neurological disorders. JAMA Neurol. 
2020;77:927–8.
 16. Jankovic J. Motor fluctuations and dyskinesias in Parkinson’s disease: clini‑
cal manifestations. Mov Disord. 2005;20:S11–6.
 17. Van der Kolk NM, Overeem S, De Vries NM, Kessels RP, Donders R, Brouwer 
M, Berg D, Post B, Bloem BR. Design of the park‑in‑shape study: a phase 
Page 6 of 6van Kersbergen et al. BMC Res Notes          (2021) 14:329 
•
 
fast, convenient online submission
 •
  
thorough peer review by experienced researchers in your field
• 
 
rapid publication on acceptance
• 
 
support for research data, including large and complex data types
•
  
gold Open Access which fosters wider collaboration and increased citations 
 
maximum visibility for your research: over 100M website views per year •
  At BMC, research is always in progress.
Learn more biomedcentral.com/submissions
Ready to submit your research ?  Choose BMC and benefit from: 
II double blind randomized controlled trial evaluating the effects of 
exercise on motor and non‑motor symptoms in Parkinson’s disease. BMC 
Neurol. 2015;15:56.
 18. Podsiadle D, Richardson S. The timed up and go: a test of basic functional 
mobility for frail elderly persons. J Am Geriatr Soc. 1991;39:142–84.
 19. Steinert A, Sattler I, Otte K, Röhling H, Mansow‑Model S, Müller‑Werdan U. 
Using new camera‑based technologies for gait analysis in older adults in 
comparison to the established GaitRite system. Sensors. 2020;20:125.
 20. Ebersbach G, Edler D, Kaufhold O, Wissel J. Whole body vibration versus 
conventional physiotherapy to improve balance and gait in Parkinson’s 
disease. Phys Med Rehabilitat. 2008;89:399–403.
 21. Gobbi L, Oliveira‑Ferreira M, Caetano M, Lirani‑Silva E, Barbieri F, Stella F, 
Gobbi S. Exercise programs improve mobility and balance in people with 
Parkinson’s disease. Parkinsonism Relat Disord. 2009;1553:49–52.
 22. Guralnik JM, Simonsick EM, Ferrucci L, Glynn RJ, Berkman LF, Blazer DG, 
Scherr PA, Wallace RB. A short physical performance battery assess‑
ing lower extremity function: association with self‑reported disability 
and prediction of mortality and nursing home admission. J Gerontol. 
1994;49:85–94.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub‑
lished maps and institutional affiliations.
